Hospira, Inc.  

(Public, NYSE:HSP)   Watch this stock  
Find more results for Hospira
87.95
+0.24 (0.27%)
Mar 4 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 87.64 - 87.97
52 week 40.41 - 87.97
Open 87.69
Vol / Avg. 0.00/4.50M
Mkt cap 15.01B
P/E 45.08
Div/yield     -
EPS 1.95
Shares 171.09M
Beta 0.70
Inst. own 92%
Apr 28, 2015
Q1 2015 Hospira Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 12, 2015
Q4 2014 Hospira Inc Earnings Release
Feb 5, 2015
Pfizer Inc Discussing Proposed Acquisition of Hospira Call (Media)
Feb 5, 2015
Pfizer Inc Discussing Proposed Acquisition of Hospira Call (Analyst and Investor)
Jan 14, 2015
Hospira Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 14, 2015
Hospira Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 3.03% 7.09%
Operating margin 3.52% 10.45%
EBITD margin - 16.11%
Return on average assets 2.08% 4.93%
Return on average equity 4.29% 10.58%
Employees 19,000 -
CDP Score - 58 E

Address

275 N Field Dr
LAKE FOREST, IL 60045-2579
United States - Map
+1-847-9376472 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Hospira, Inc. (Hospira) is a provider of injectable drugs and infusion technologies. Hospira's portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Hospira conducts operations worldwide and is managed in three reportable segments: Americas; Europe, Middle East and Africa (EMEA), and Asia Pacific (APAC). The Americas segment includes the United States, Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa, and the APAC segment includes Asia, Japan, Australia and New Zealand. In all segments, Hospira sells a line of products, including specialty injectable and other pharmaceuticals and medication management products. In July 2014, Hospira Inc acquired active pharmaceutical ingredient (API) manufacturing facility and an associated research and development (R&D) facility from Orchid Chemicals & Pharmaceuticals Ltd.

Officers and directors

F. Michael Ball Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Thomas E. Werner Chief Financial Officer, Senior Vice President - Finance
Age: 57
Bio & Compensation  - Reuters
David J. Endicott President, Hospira Medical Devices
Age: 50
Bio & Compensation  - Reuters
Kenneth F. Meyers Chief Human Resource Officer, Senior Vice President
Age: 53
Bio & Compensation  - Reuters
Mary A. Gendron Senior Vice President, Chief Information Officer
Age: 49
Bio & Compensation  - Reuters
Daphne E. Jones Chief Information Officer, Senior Vice President
Age: 56
Bio & Compensation  - Reuters
Sumant Ramachandra M.D., Ph.D. Senior Vice President, Chief Scientific Officer
Age: 46
Bio & Compensation  - Reuters
Brian J. Smith Senior Vice President, Special Counsel
Age: 63
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard John Davies Senior Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
John B. Elliot Senior Vice President - International Pharmaceutical Operations
Age: 62
Bio & Compensation  - Reuters